Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cassandra Calabrese

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Annals of the Rheumatic Diseases|April 12, 2026
Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry studyDeanna P Jannat-Khah, Pankti Reid, Laura C Cappelli, et al.
Journal for Immunotherapy of Cancer|May 28, 2026
Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort studyAlice Tison, Deanna Jannat-Khah, Laura C Cappelli, et al.
Annals of the Rheumatic Diseases|April 5, 2023
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritisAnne R Bass, Noha Abdel-Wahab, Pankti D Reid, et al.
Vaccines|May 5, 2021
Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 VaccinationAbdulla Watad, Gabriele De Marco, Hussein Mahajna, et al.
Seminars in Arthritis and Rheumatism|November 13, 2022
Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working groupNilasha Ghosh, Nina Couette, Wouter H van Binsbergen, et al.
Journal of the American Academy of Dermatology|January 10, 2021
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatmentsJoel M Gelfand, April W Armstrong, Stacie Bell, et al.
Journal of the American Academy of Dermatology|September 6, 2020
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1Joel M Gelfand, April W Armstrong, Stacie Bell, et al.
Journal for Immunotherapy of Cancer|October 15, 2025
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitorsLing Zhu, Yee-Ming M Cheung, Cherie Chiang, et al.
Arthritis Care & Research|January 4, 2023
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal DiseasesAnne R Bass, Eliza Chakravarty, Elie A Akl, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 4, 2023
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal DiseasesAnne R Bass, Eliza Chakravarty, Elie A Akl, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Annals of the Rheumatic Diseases|April 12, 2026
Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry studyDeanna P Jannat-Khah, Pankti Reid, Laura C Cappelli, et al.
Journal for Immunotherapy of Cancer|May 28, 2026
Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort studyAlice Tison, Deanna Jannat-Khah, Laura C Cappelli, et al.
Annals of the Rheumatic Diseases|April 5, 2023
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritisAnne R Bass, Noha Abdel-Wahab, Pankti D Reid, et al.
Vaccines|May 5, 2021
Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 VaccinationAbdulla Watad, Gabriele De Marco, Hussein Mahajna, et al.
Seminars in Arthritis and Rheumatism|November 13, 2022
Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working groupNilasha Ghosh, Nina Couette, Wouter H van Binsbergen, et al.
Journal of the American Academy of Dermatology|January 10, 2021
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatmentsJoel M Gelfand, April W Armstrong, Stacie Bell, et al.
Journal of the American Academy of Dermatology|September 6, 2020
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1Joel M Gelfand, April W Armstrong, Stacie Bell, et al.
Journal for Immunotherapy of Cancer|October 15, 2025
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitorsLing Zhu, Yee-Ming M Cheung, Cherie Chiang, et al.
Arthritis Care & Research|January 4, 2023
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal DiseasesAnne R Bass, Eliza Chakravarty, Elie A Akl, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 4, 2023
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal DiseasesAnne R Bass, Eliza Chakravarty, Elie A Akl, et al.
Pageof 7